In the ICI‐chemotherapy combination group, studies employing anti‐PD‐L1 drugs were associated with a higher rate of grade 3–5 AEs compared with anti‐PD1 drugs in first line for NSCLC (p = 0.0302). Here, CD274 is linked to non-small cell lung carcinoma.